New Stock News | Simatai Hong Kong IPO Prospectus Invalid

10:34 20/03/2026

Simatec Information Group Co., Ltd. (referred to as Simatec), whose Hong Kong IPO prospectus was submitted on September 19, 2025, expired after 6 months on March 19, 2026. Haitong International, CITIC Securities, and CITIC Jiantou International were the joint underwriters at the time of submission.

Simatec Information Group Co., Ltd. (hereinafter referred to as "Simatec") submitted its Hong Kong IPO prospectus on September 19, 2025, which expired on March 19, 2026 after six months, with HAITONG INT'L, CITIC SEC, and China Securities Co., Ltd. International as joint sponsors. According to the prospectus, Simatec is a leading provider of intelligent industrial software solutions in China. With proprietary technology and independent intellectual property rights, it has developed the industry's first and only full-stack intelligent manufacturing and operational management software solutions. According to the same source, based on the industrial software revenue of advanced industries in 2024, the company is the largest Chinese provider in the market for advanced industrial intelligent manufacturing software companies in China. Based on the same source, among the top ten Chinese intelligent manufacturing software companies ranked by revenue from advanced industries in 2024, it is also the fastest growing company based on the compound annual growth rate of relevant revenue from 2022 to 2024.

Focusing on "The 15th Five-Year Plan", AI + finance is becoming a driving force for promoting consumption and infrastructure construction. QiFu Technology was invited to attend the China Development High-Level Forum.

HK Stock Market Move | Property insurance stocks across the board fell, sparking market turmoil as insurers faced pressure from end-of-quarter solvency assessment. Institutions warned against exaggerating the impact.

The only one in the world! GRAND PHARMA (00512) has obtained domestic approval for a groundbreaking innovative eye medicine, benefiting millions of patients, and the volume of nuclear medicine will accelerate again by 2025.